How to respond to signs of mild cognitive impairment and memory loss
Q. Two members of our book group have early signs of cognitive impairment. We have become so close after 10 years of being ...
Study finds intensive blood pressure control reduces risk of cognitive impairment
A new study from researchers at Wake Forest University School of Medicine shows that only 3.5 years of intensive blood ...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...
Treating hypertension may help lower cognitive decline risk
Intensive blood pressure control for adults with hypertension and high cardiovascular risk can reduce the risk of mild ...
PharmaTimes4d
FDA approves new Alzheimer’s treatment regimen
The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...
Medscape22h
EMA to Review New Safety Data on Alzheimer’s Drug Leqembi
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Biogen provides update on EU regulatory review of lecanemab in Alzheimer’s
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Neurology Advisor4d
Oral SIGMAR1 Targeting Agent Looks Promising in Early Alzheimer Disease Trial
Topline data were published from a phase 2b/3 study evaluating blarcamesine for the treatment of early Alzheimer disease.
Press-Telegram12d
How to respond to signs of mild cognitive impairment and memory loss
Many thanks, L.E. The Alzheimer’s Association defines mild cognitive impairment (MCI) as an early stage of memory loss or other cognitive abilities, which may include the use of language or ...